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Abstract Breast cancer is the most common type of cancer and the leading cause of cancer-
related death among women worldwide. Hormone receptor-positive (HRþ) tumors
represent the most common form of this disease, with more than 70% of breast
cancers expressing these receptors. Response and benefit to neoadjuvant chemo-
therapy (NCT) varies according to HR expression, with lower responses in luminal
tumors as compared with hormone receptor-negative (HR-) and human epidermal
growth factor receptor 2-positive (HER2þ) tumors. Neoadjuvant endocrine therapy
(NET) is an option for selected patients with HRþ locally advanced breast cancer.
Neoadjuvant endocrine therapy has a favorable toxicity profile, and is associated
with benefits such as having low cost and being more easily available even for cancer
care professionals outside major urban areas or tertiary centers. These factors are
particularly relevant, as 70% of breast cancer deaths occur in women from low-
income and middle-income countries. Additionally, NET is being increasingly
explored, not simply to allow for less extensive surgery, but also as a scientific
tool, with the use of biomarkers to predict outcomes in adjuvant trials and for the
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Introduction
Breast cancer is a heterogeneous group of diseases with
different histological, prognostic and clinical aspects.1 Hor-
mone receptor positive (HR þ ) tumors represent the most
common form of breast cancer, and account for most of the
deaths from this disease. Modern treatment strategies are
tailored to molecular subtypes,2 allowing a more individual-
ized approach to therapy.
Early stage breast cancer treatment involves three main
therapeutic modalities: surgery, systemic therapy and
radiation therapy. Systemic therapies refer to the admin-
istration of drugs that spread throughout the body to treat
cancer cells wherever they may be. They include chemo-
therapy, hormonal therapy, immunotherapy, and biolog-
icals such as monoclonal antibodies. Traditionally,
systemic therapy has been administered after surgery.
Pivotal trials have demonstrated that neoadjuvant (preop-
erative) chemotherapy (NCT) is safe and equivalent to
adjuvant chemotherapy in terms of risk of recurrence
and overall survival (OS).3,4 Additionally, neoadjuvant
chemotherapy induces tumor downstaging and increases
the rates of breast-conserving surgery (BCS).5
Neoadjuvant endocrine therapy (NET) is an attractive
alternative to NCT for estrogen receptor (ER)-positive tu-
mors, given the fact that it is simple to deliver and a well-
tolerated targeted therapy. The potential of NET is being
increasingly explored, not simply to allow for less extensive
surgery, but also as a scientific tool, with the use of biomark-
ers to predict outcomes both in adjuvant trials and for the
individual patient.6 Although currently available endocrine
therapy (ET) agents are generally effective and well-tolerat-
ed, not all patients benefit equally. Predictive biomarkers
should facilitate a more rational approach to HRþ breast
cancer. A better understanding of the features underlying
heterogeneity, as well as the mechanisms of resistance to
ET,7 is essential for the development of novel therapies.
Neoadjuvant treatment modalities require a close collab-
oration between oncology professionals, including surgeons,
gynecologists, medical oncologists, radiation oncologists
and pathologists. This review details the current and most
relevant evidence about neoadjuvant endocrine therapy for
breast cancer, as well as the future directions of this field.
Neoadjuvant Endocrine Therapy as a Clinical
Tool
The development of precision medicine for the treatment of
locally advanced breast cancer (LABC) is an appealing con-
cept. The treatment algorithm for HRþ in both the adjuvant
and metastatic settings is evolving. Recent developments
have elucidated the molecular interactions of HR signaling
with other important growth factors: metabolic and cell
division pathways. These studies have opened the possibility
of improving results while modulating these interactions
and interfering with resistance mechanisms.7 Therefore,
new approaches to treatment have been tested, some of
which (that is, the use of genetic signature panels to individ-
ualize the adjuvant treatment as well as the use of mecha-
nistic Target of Rapamycin [mTOR] and cyclin-dependent
kinase [CDK] 4/6 inhibition) have been incorporated in the
clinical practice.8 However, despite the developments
achieved and the exciting perspectives for the future, we
have been unable to fully integrate the concept that different
patients have different degrees of endocrine dependency and
sensitivity to chemotherapy in the neoadjuvant setting.
It is known that the response and benefit to NCT varies
according to HR expression, with lower responses in luminal
individual patient. This review details the current and most relevant evidence about
NET for breast cancer as well as the future directions of this field.
Resumo O câncer de mama é o mais comum, e a principal causa de mortalidade por câncer em
mulheres de todo o mundo. Os tumores com receptor hormonal (RH) positivo
representam o tipo mais comum desta doença. O benefício e as taxas de resposta à
quimioterapia neoadjuvante variam de acordo com a expressão de RH, sendo mais
baixa nos tumores luminais em comparação com tumores HER2 positivos ou triplo-
negativos. A hormonioterapia neoadjuvante, uma opção para pacientes selecionados
com tumores RH positivo localmente avançados, apresenta melhor perfil de tolerabi-
lidade e segurança, e está associada com benefícios adicionais, como baixo custo e fácil
acesso. Estes fatores são relevantes, uma vez que 70% das mortes por câncer de mama
acontecem em mulheres de países pobres ou em desenvolvimento. Além disso, a
hormonioterapia neoadjuvante vem sendo explorada como uma ferramenta científica,
ao possibilitar o estudo de biomarcadores que podem predizer desfechos tanto para
pacientes individuais quanto para ensaios clínicos em adjuvância. Este artigo de revisão
detalha o conhecimento atual e as evidências mais relevantes sobre hormonioterapia
neoadjuvante em câncer de mama, assim como perspectivas futuras nesta área.
Palavras-chave
► neoplasias da mama
► farmacoterapia
► tamoxifeno
► inibidores da
aromatase
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tumors as compared with HR- and HER2þ tumors that are
associated with lower pathological complete response (pCR)
rates.9,10 In patients with luminal tumors, endocrine therapy
probably accounts for most of the gains obtained with the
adjuvant systemic treatment, and the need for chemotherapy in
these patients remains controversial. The absolute OS benefit
with adjuvant chemotherapy in postmenopausal women with
HRþ breast cancer is no higher than 3–4%.11 Furthermore, data
from large phase III trials provide evidence that adjuvant
chemotherapy has limited benefits for ER-rich tumors. This
view is supported by recent studies of genetic signatures in
which the majority of patients with luminal tumors have low-
risk disease and excellent prognosis with adjuvant ET alone.
Neoadjuvant endocrine therapy was initially used in the
early 1980s as a therapeutic option for elderly womenwho
were ineligible for surgery and unfit to be treated with
chemotherapy.12 Initial studies were designed to evaluate
the role of the endocrine treatment as a primary thera-
peutic option as an alternative to surgery, rather than as a
neoadjuvant treatment.13 Most of these studies reported
response rates of over 50%.12,13 A significant higher local
regional relapse rate,14 and possibly a decrease in OS15was
observed in the group of patients not treated with surgery,
although these differences emerged only after a follow-up
of a couple of years.16 These trials discouraged the use of
preoperative ET instead of surgery, but nevertheless
showed the approach to be reasonable for patients unfit
for surgery.6
Modern NET approaches have two main objectives: tumor
downstaging to allow for breast-conserving surgery (BCS) and
in vivo analysis of sensitivity or resistance to the endocrine
treatment. Although endocrine therapy resistance in ad-
vanced disease is clinically obvious and is associated with
incurability, the detection (or prediction) of ET resistance in
primary tumors before relapse remains a crucial research
field, because early-stage disease is still within the “curability
window”.7
NET has a favorable toxicity profile, especially in compar-
ison with anthracycline and taxane-based chemotherapy.
Still, endocrine manipulation is associated with additional
potential benefits, such as having low cost and being easily
andmore rapidly available even for cancer care professionals
outside major urban areas or tertiary centers. These factors
are particularly relevant, as breast cancer is the most com-
mon cancer in women worldwide, and 70% of breast cancer
deaths occur in women from low-income and middle-in-
come countries.17 Brazil has a population with diverse
ethnic, cultural, and socioeconomic backgrounds, and provi-
sion of health care throughout the country is a major
challenge.
Nonetheless, it could be stated that there are still more
questions than answers regarding NET. The lack of standard-
ized predictive biomarkers and evaluation of the evaluation,
the paucity of clinical trials comparing modern NET and NCT
strategies, the doubts regarding adjuvant treatment after
NET, and the lack of prospective data evaluating the safety of
withholding chemotherapy in LABCs are caveats that need to
be addressed and constitute a priority for future research
within this field.
Current Available Data
• What is the best endocrine agent?
The third generation aromatase inhibitors (AIs) anastro-
zole, letrozole and exemestane are currently the standard
treatment forHRþ breast cancerwhenNET is considered.
This is also true both in the adjuvant and metastatic
settings, basedon several clinical trials thatdemonstrated
their superiority over tamoxifen.8,18 Randomized clinical
trials evaluating this issue in the neoadjuvant setting are
summarized in ►Table 1. The balance of evidence from
the trials shows that AIs aremore effective clinically than
tamoxifen in achieving response and in down-staging to
avoid mastectomy or to convert inoperable tumors into
operable ones.19 A meta-analysis including a total of
1,160 patients indicated superior outcomes in terms of
clinical objective response rate, ultrasound response rate,
and BCS rate with AIs when compared with tamoxifen.
The American College of Surgeons Oncology Group (ACO-
SOG) Z103120 trial compared exemestane, letrozole and
anastrozole head-to-head in the neoadjuvant setting, and
showed that the effectiveness of the three agents is
equivalent. This question was evaluated in the premeno-
pausal population on the STAGE trial that demonstrated
superior response rate, favoring anastrozole plus goser-
elin in comparison with tamoxifen plus goserelin.
Fulvestrant is a selective estrogen receptor down-
regulator (SERD) associated with increased progres-
sion free survival (PFS) and OS benefits compared with
AIs in thefirst- and second-line treatments of advanced
breast cancer.8,21–24 However, in a phase II on the
neoadjuvant setting, fulvestrant was not superior to
standard AI therapy.25
• What is the optimal duration?
Based on earlier experience with NCT, a three to four-
month duration of NET has been proposed in the
majority of the clinical trials, such as the Immediate
Preoperative Anastrozole, Tamoxifen, or Combined
with Tamoxifen (IMPACT),26 the Pre-Operative “Arimi-
dex” Compared to Tamoxifen (PROACT)27 and the
PO24.28 However, evidence from other studies sug-
gests that this periodmay be insufficient to achieve the
maximal response in terms of reduction in tumor
volume.29–33 In summary, these studies investigated
the potential benefit of the prolonged treatment with
neoadjuvant AIs, and showed that the response rate
and the rate of BCS increased after six months of NET,
with approximately one third of patients achieving
maximal reduction in tumor volume after six months.
It must be emphasized thatmost of the published trials
on NET treated patients during  3–4 months, thereby
potentially underestimating the benefits from the en-
docrine treatment. It is currently not clear if extending
NET to beyond 12 months could further improve the
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response, but there is a theoretical risk that mecha-
nisms of resistance to AI therapy7 could develop during
the treatment, triggering the event of tumor progres-
sion and even disease spread beyond the breast.34
• NET versus NCT?
There is very limited data comparing NCT and NET,19
and the best available evidence comes from two ran-
domized phase II trials (►Table 2). Semiglazov et al35
randomized 239 postmenopausal women with stage
IIA-IIIB HRþ breast cancer to receive preoperative AIs
(anastrozole or exemestane for three months) or che-
motherapy (four cycles of doxorubicin plus paclitax-
el).35 There was no statistically significant difference
between NET and NCT in terms of clinical response
rate, time to response, and pCR. The Grupo Español de
Investigación en Cáncer de Mama (GEICAM) 2006–03
trial randomized 97 patients with immunohistochem-
istry (IHC)-defined luminal disease to receive neoad-
juvant exemestane (a small proportion of
premenopausal patients also received goserelin) for
six months or chemotherapy (Adriamycin [doxorubi-
cin]/cyclophosphamide [AC] followed by docetaxel).
Although no statistically significant difference was
found between the two arms in terms of response
rate, there was a trend for a worse outcome in the
endocrine therapy arm for premenopausal patients
and those with high expression of tumor Ki67.36 The
Neoadjuvant Chemotherapy Versus Endocrine Therapy
(NEOCENT) trial,37 which was designed to address this
Table 1 Randomized trials comparing different endocrine agents in the neoadjuvant setting
Trial (ref)
phase
Treatment arm (n) Duration
(months)
Primary endpoint ORR BCS
IMPACT26
III
A: Anastrozole (113)
B: Tamoxifen (108)
C: Anastrozole þ tamoxifen (109)
3 ORR by ultrasound A: 37%
B: 36%
C: 39%
A: 44%
B: 31%
C: 29%
PO2452
III
A: Letrozole (162)B: Tamoxifen (223) 4 ORR by clinical palpation A: 55%
B: 36%
p < 0.001
A: 45%
B: 35%
p ¼ 0.02
PROACT27
III
A: Anastrozole (228)
B: Tamoxifen (223)
3 ORR by ultrasound A: 39%
B: 35%
A: 43%
B: 31%
p ¼ 0.04
ACOSOG Z101153
II
A: Exemestane (124)
B: Letrozole (128)
C: Anastrozole (125)
4 ORR by clinical palpation A: 63%
B: 75%
C: 69%
A: 48%
B: 41%
C: 64%
STAGE20
III
A: Anastrozole (þ goserelin) (98)
B: Tamoxifen (þ goserelin) (98)
6 ORR by caliper A: 70%
B: 50%
p ¼ 0.004
A: 86%
B: 68%
RUSSIAN TRIAL54
II
A: Exemestane (76)
B: Tamoxifen (75)
3 ORR by clinical palpation A: 76%
B: 40%
p ¼ 0.05
A: 37%
B: 25%
p ¼ 0.05
CARMINA25
II
A: Anastrozole (57)
B: Fulvestrant 500 mg (59)
4–6 ORR by clinical palpation A: 62%
B: 46%
A: 59%
B: 49%
Abbreviations: BCS, breast-conserving surgery; CARMINA; IMPACT, Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen;
ORR, overall response rate; PO24; PROACT, Pre-Operative “Arimidex” Compared to Tamoxifen; STAGE.
Table 2 Randomized trials comparing endocrine versus chemotherapy in the neoadjuvant setting
Trial (ref) Treatment arm (n) Duration Primary endpoint ORR BCS
Semiglazov et al35 A: Chemotherapy (118)
(doxorrubicin þ paclitaxel)
B: Endocrine therapy (121)
(anastrozole 61) (Exemestane 60)
3 months ORR by clinical palpation A:63%
B: 64%
A: 24%
B: 33%
p ¼ 0.058
GEICAM 2006–0336 A: Chemotherapy
(EC- > docetaxel)
B: Exemestane
(plus goserelin if premenopausal)
Response rate by MRI A: 66%
B: 48%
A: 47%
B: 56%
NEOCENT37 A: Chemotherapy (22)
B: letrozole (22)
18–23 weeks Recruitment feasibility
and tissue collection
A: 54%
B: 59%
Abbreviations: BCS, breast-conserving surgery; EC, epirrubicin þ cyclophosphamide; GEICAM, Grupo Español de Investigación en Cáncer de Mama;
MRI, magnetic resonance imaging; NEOCENT, neoadjuvant chemotherapy versus endocrine therapy; ORR, overall response rate.
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important question (comparing NCT and NET), was
unfortunately closed due to slow accrual. Given the
evidence regarding the modest efficacy of chemother-
apy for HRþ disease in both the adjuvant and the
neoadjuvant settings, and the feasibility, efficacy and
activity of NET, a comparison of NCT and NET in the
context of HR-rich disease is required, and should be
considered a priority in breast cancer clinical research.
• NET in premenopausal patients
Data are very limited on NET in premenopausal wom-
en. A Japanese trial compared the efficacy of anastro-
zole with goserelin versus tamoxifenwith goserelin for
24 weeks preoperatively in 197 premenopausal pa-
tients with ERþ HER2- early breast cancer. The overall
response rate was 70.4% in the anastrozole group. This
finding correlates with the recently reported practice-
changing Suppression of Ovarian Function Trial (SOFT)
38 and Tamoxifen and Exemestane Trial (TEXT),39
which demonstrated a significant benefit in terms of
recurrence-free survival for ovarian function suppres-
sion plus an AI in comparison with tamoxifen in
premenopausal patients with high-risk early breast
cancer. These results are encouraging, and suggest
that an AI plus ovarian function suppression is an
effective treatment option in this patient population.
However, until this question is adequately evaluated in
large prospective randomized trials, NET in premeno-
pausal patients should be considered experimental.
Neoadjuvant Endocrine Therapy in 2016
take home messages
• Ideal candidates: postmenopausal patients with
ER-enriched stage II-III breast cancer
• AIs superior to tamoxifen
• Anastrozole, letrozole and exemestane are
equivalent
• Optimal duration: 6 months (at least)
• Clinical response rate ¼ 50–70%
• Downstaging to BCS ¼ 30–50%
Outcomes and Response Evaluation in NET
Neoadjuvant systemic therapy (NAST) provides valuable
information for patients, clinicians and researchers. Howev-
er, there is significant variability in the methods of the
pathological assessment of the response to the neoadjuvant
systemic treatment, and therefore, there is also significant
variability in their interpretation for subsequent clinical
decisions. Pathological complete response (pCR), defined as
the absence of invasive disease in both the breast and the
lymph nodes, is frequently considered an intermediate
endpoint to predict the long-term outcome following NCT.
Recently, the US Food and Drug Administration (FDA) has
recommended pCR as an endpoint for the accelerated
approval of new agents for neoadjuvant treatment for
high-risk early-stage breast cancer, and has recently ap-
proved pertuzumab based on the increase in the pCR
rate.40 International collaboration groups have published
recommendations for the standardized pathological charac-
terization of residual disease for the neoadjuvant clinical
trials of breast cancer. The use of pCR to demonstrate the
treatment efficacy of novel therapies requires a standard
definition and approach to pCR assessment. A standard
approach to the post-NAST pathological assessment of breast
cancer would improve comparisons between clinical trials
and enable the accumulation of more robust evidence in
controversial areas of practice, such as specimen handling,
and better serve each patient. Unfortunately, there is paucity
of evidence and recommendations regarding the pathologi-
cal evaluation after NET.
In the meta-analysis of the Collaborative Trials in Neo-
adjuvant Breast Cancer (CTNeoBC), patients who achieved
pCR had a 52% reduction in the probability of an event
(p < 0.001) and a 64% reduction in the probability of death
(p < 0.001).41 The achievement of pCR was highly variable
by tumor subtype, with aggressive tumor subtypes more
likely associatedwith event-free survival than smaller, less
aggressive tumors. Pathological complete responses were
more uncommon in patients with low-grade HRþ tumors
(7%) than among patients with tumors that were high-
grade HRþ (16%), triple-negative (34%), HR þ /HER2þ
(30%), and HR-/HER2þ (50%). The Food and Drug Adminis-
tration accepts two definitions of pCR as an endpoint to
support accelerated drug approval: ypT0 ypN0 (that is,
absence of residual invasive and in situ cancer in the breast
and axillary lymph nodes following the completion of the
neoadjuvant therapy) and ypT0/Tis ypN0 (absence of re-
sidual invasive cancer in the breast and lymph nodes,
irrespective of ductal carcinoma in situ [DCIS]). Event-
free survival and OS were shown similar for ypT0 and
ypT0/Tis ypN0. Residual DCIS was not associated with
the prognostic value.41
Pathological complete remissions are infrequent with
NET and, as such, have not demonstrated prognostic or
predictive value. Some systems, such as the Residual
Cancer Burden (RCB)42 index, are used to quantify the
amount of cancer remaining after treatment, and are being
incorporated into research protocols. Is has been demon-
strated that patients with minimal invasive residual dis-
ease have a better prognosis in comparison with patients
with higher volume of residual disease after NCT, demon-
strating a pattern of resistance to systemic therapy. This
interesting approach, however, has not been validated
after endocrine treatment.
Interestingly, and in contrast to NCT, preoperative AIs have
been reported as producing the histological feature of central
scarring with a statistically significant correlation between
central scarring and clinical tumor volume reduction.43 This
observation requires validation, but, if confirmed, central
scarring could be explored as a surrogate predictive endpoint.
The pathologist plays a key role in determining the extent
and types of response to therapy. To achieve the maximum
amount of information, careful pretreatment tumor and
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lymph node sampling, and close communication among the
surgeon, the medical oncologist, the radiologists and the
pathologist is mandatory.
Neoadjuvant Endocrine Therapy as a
Scientific Tool
Besides the advantages discussed before, NET can be a very
useful scientific tool. The evaluation of treatment response in
vivo is of the utmost importance, especiallywhen the disease
is still potentially curable. A crucial aspect in the use of NET is
how to determine treatment success. It has been discussed
previously howpCR is not a good parameter to determine the
response to NET, and how it is not a good predictive and
prognostic marker in this setting. With that in mind, Ellis et
al,28 in the early 2000’s, developed a research strategy to
evaluate the response to NET based on intuitive methods
used in the clinical management of patients. As a patient is
diagnosed with high blood pressure, a clinician would start
him on a drug, losartan for example, and then measure the
patient’s blood pressure after a few days or weeks and
evaluate treatment success.
Using this logical approach, Ellis’ group investigated the
utility of Ki-67 as a possible predictive biomarker to treat-
ment response. Ki-67 is one of the most widely used prolif-
eration markers in breast cancer. The relationships between
Ki-67 and outcomes are greatly clarified when Ki-67 levels
are measured after the initiation of the neoadjuvant endo-
crine therapy.28,44,45 In 2008, Ellis et al28 published the
preoperative endocrine prognostic index (PEPI) score, in-
cluding tumor size, nodal status, ER status and Ki-67 score.
Patients that achieved a PEPI score of 0 after 16–18 weeks of
NET were considered to have very low risk of relapse, and
weren’t likely to benefit from adjuvant chemotherapy. The
PEPI score was then evaluated on the Z1031 trial that
randomized 377 post-menopausal, stage II and III, ERþ
breast cancer patients to receive NET. The time to breast
cancer recurrencewas decreased among thosewith PEPI > 0
status relative to those with PEPI-0 status. Only one disease
event among 44 (2%) cases with PEPI-0 was observed, versus
26 out of 158 cases (16.5%) with PEPI > 0. This study showed
the PEPI score is a valid clinical trial endpoint to identify
patients with very low relapse risk after NET, and, therefore,
it has operational characteristics similar to pCR after che-
motherapy for ER- disease.46 On an extension of the Z1031
trial, the group activated the Z1031 trial cohort B. In that arm,
the group developed a strategy to evaluate the response to
NET in which, after 2–4 weeks of ET, patients would have
another biopsy to evaluate Ki-67 and other parameters. With
a Ki-67 higher than 10%, patients would be considered
resistant to ET, andwould be triaged to eitherNCTor surgery;
if Ki-67 was lower than 10%, patients would be considered
sensitive to NET, and would complete 16–18 weeks of NET.
They concluded that a Ki67 value > 10% at 2 to 4 weeks
strongly enriches for high-risk molecular subtypes (mainly
luminal B [LumB]), and should bemanagedwith the addition
of chemotherapy to their treatment plan. The results of the
longer follow-up of that trial are expected in 2016.47
In 2012, Goncalves et al48 evaluated another interesting
feature of Ki-67 in the NET setting. By comparing adjuvant
and neoadjuvant endocrine treatment trials, the authors
identified a very provocative pattern. Based on the pharma-
codynamic property of Ki-67 while on endocrine treatment,
that is, the reduction of Ki-67, results of small, shorter, less
expensive NET trials predicted with surprising accuracy the
results of adjuvant trials that were longer (requiring at least
5 years of follow-up) and required thousands of patients,
being, therefore, very expensive. At a time in which the cost
of research is increasingly higher and research funding is
limited, the activation of an adjuvant endocrine treatment
trial should be preceded by promising results in the neo-
adjuvant setting.
Future Perspectives
Neoadjuvant endocrine therapy trials are the ideal scenario
to study biomarkers, andmuch has been accomplished using
Ki67, ER status and PEPI score. Besides prognostic informa-
tion (PEPI score) and better patient selection (ER and Ki67),
NET also identifies endocrine resistant tumors whose prog-
nosis might only be improved through the combinationwith
target therapies or with chemotherapy. Most of the current
available target therapies have been investigated in associa-
tion with endocrine therapy on metastatic patients in mixed
endocrine resistance stages (endocrine naïve, acquired re-
sistance and de novo resistance). The ongoing NET trials
using endocrine therapy combined with various target
agents (CDK inhibitors, mTOR inhibitors, phosphoinositide
3-kinase [PI3K] inhibitors and HER2 targets) have the advan-
tage of addressing endocrine naïve patients, optimizing the
study of biomarker development with tumor tissue analysis
and treatment efficacy assessment.
One of the main limitations of NET trials is their small
sample size due to patient selection and the general fear of
tumor progression during NET. The collection of biological
material is usually performed at 2 or 3 time periods during
the neoadjuvant treatment to allow for pre-treatment and
on-treatment biomarker analysis and evaluation of prognos-
tic and predictive factors.49 The acquisition of on-treatment
specimens is also a valuable resource for genomic profiling
studies that will enlighten us on the mutational background
of treatment-responsive and treatment-resistant tumors,
possibly leading to more tailored strategies.50
Conclusion
Chemotherapy has been the mainstay modality in the neo-
adjuvant treatment of breast cancer since the landmarkNation-
al Surgical Adjuvant Breast and Bowel Project (NASBP) B-18
trial,which compared the sameanthracycline-based regimen in
the adjuvant and the neoadjuvant settings.4 Since then, the
characterization of breast cancer subtypes has directed us to a
more rational treatment approach to the disease. The chemo-
therapy strategy is particularly adequate for triple-negative
breast cancers and for HER2þ disease (in combination with
anti-HER2agents),with a consistenthighpCR.At the sametime,
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the added benefit of chemotherapy for the larger and heteroge-
neous HRþ subgroup has been challenged.
Neoadjuvant endocrine therapy is a rational approach
that provides an outstanding opportunity to further individ-
ualize treatment selection. However, it has been timidly
evaluated in the clinical trials, and implemented rarely in
the clinical practice. According to the National Cancer Data-
base, in the US, only 3% of the eligible patients receive this
therapy.51
The multiple breast cancer molecular profiles and their
translation into usable tumor and serum platforms may
provide the basis for NET. At the same time, the remarkable
improvement recently demonstrated, and the ongoing
research in advanced breast cancer with the combination
of endocrine agents with PI3K and CDK inhibitors will likely
be incorporated in earlier stage diseases. An increased im-
petus to NET is likely to come in the following years.
Methods Supplement
Selected trials included in a recently published systematic
review andmeta-analysis were evaluated.19A descriptive
synthesis was planned, as we did not expect the data to be
sufficiently homogeneous to allow for direct comparisons
and definitive statements. Our objective was to perform a
comprehensive review focused on the most important
patient care related aspects. Based on Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines, Spring et al19 selected twenty pro-
spective, randomized, neoadjuvant clinical trials that
reported response rates with at least one arm incorporat-
ing NET.
In our analysis, ten studies were considered: three studies
comparing NET monotherapy with AIs and combination
NCT for localized breast cancer, and seven studies com-
paring NETmonotherapywith different endocrine agents.
Trials evaluating NET with growth factor pathway inhib-
itors and studies without direct comparison were not
included.
Acknowledgments
TR, SR and RG gratefully acknowledge Dr. Matthew Ellis
for the mentorship that led to the conception of this
manuscript.
References
1 Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical manage-
ment of breast cancer heterogeneity. Nat Rev Clin Oncol 2015;
12(7):381–394
2 Kravchenko J, Akushevich I, Seewaldt VL, Abernethy AP, LyerlyHK.
Breast cancer as heterogeneous disease: contributing factors and
carcinogenesis mechanisms. Breast Cancer Res Treat 2011;
128(2):483–493
3 Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant
systemic treatment in breast cancer: a meta-analysis. J Natl
Cancer Inst 2005;97(3):188–194
4 Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative
chemotherapy on the outcome of women with operable breast
cancer. J Clin Oncol 1998;16(8):2672–2685
5 Eiermann W, Pienkowski T, Crown J, et al. Phase III study of
doxorubicin/cyclophosphamide with concomitant versus se-
quential docetaxel as adjuvant treatment in patients with human
epidermal growth factor receptor 2-normal, node-positive breast
cancer: BCIRG-005 trial. J Clin Oncol 2011;29(29):3877–3884
6 Smith IE. Preoperativeendocrine therapy foroperablebreastcancer.
In:Harris JR, LippmanME,MorrowM,OsborneCK,editors. Diseases
of the breast. 5th ed. Philadelphia: Wolters Kluwer; 2014:754–763
7 Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aroma-
tase inhibitor resistance. Nat Rev Cancer 2015;15(5):261–275
8 Reinert T, Barrios CH. Optimal management of hormone receptor
positive metastatic breast cancer in 2016. Ther Adv Med Oncol
2015;7(6):304–320
9 Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more
effective in patients with breast cancer not expressing steroid
hormone receptors: a study of preoperative treatment. Clin
Cancer Res 2004;10(19):6622–6628
10 Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic
complete response after primary chemotherapy in relation to
hormone receptor status and other factors. J Clin Oncol 2006;
24(7):1037–1044
11 Peto R, Davies C, Godwin J, et al; Early Breast Cancer Trialists’
Collaborative Group (EBCTCG). Comparisons between different
polychemotherapy regimens for early breast cancer: meta-analy-
ses of long-term outcome among 100,000 women in 123 ran-
domised trials. Lancet 2012;379(9814):432–444
12 Preece PE, Wood RA, Mackie CR, Cuschieri A. Tamoxifen as initial
sole treatment of localised breast cancer in elderlywomen: a pilot
study. Br Med J (Clin Res Ed) 1982;284(6319):869–870
13 Gazet JC,Markopoulos C, Ford HT, Coombes RC, Bland JM, Dixon RC.
Prospective randomised trial of tamoxifen versus surgery in elderly
patients with breast cancer. Lancet 1988;1(8587):679–681
14 Bates T, Riley DL, Houghton J, Fallowfield L, Baum M; The Elderly
Breast Cancer Working Party. Breast cancer in elderly women: a
Cancer Research Campaign trial comparing treatment with ta-
moxifen and optimal surgery with tamoxifen alone. Br J Surg
1991;78(5):591–594
15 Fennessy M, Bates T, MacRae K, Riley D, Houghton J, BaumM. Late
follow-up of a randomized trial of surgery plus tamoxifen versus
tamoxifen alone in women aged over 70 years with operable
breast cancer. Br J Surg 2004;91(6):699–704
16 Mustacchi G, Ceccherini R, Milani S, et al; Italian Cooperative
Group GRETA. Tamoxifen alone versus adjuvant tamoxifen for
operable breast cancer of the elderly: long-term results of the
phase III randomized controlled multicenter GRETA trial. Ann
Oncol 2003;14(3):414–420
17 Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE.
Breast cancer in Brazil: present status and future goals. Lancet
Oncol 2012;13(3):e95–e102
18 DowsettM, Forbes JF, Bradley R, et al; Early Breast Cancer Trialists’
Collaborative Group (EBCTCG). Aromatase inhibitors versus
tamoxifen in early breast cancer: patient-level meta-analysis of
the randomised trials. Lancet 2015;386(10001):1341–1352
19 Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine
therapy for estrogen receptor–positive breast cancer a systematic
review and meta-analysis. JAMA Oncol 2016;2(11):1477–1486
20 EllisMJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant
comparison between letrozole, anastrozole, and exemestane for
postmenopausal women with estrogen receptor-rich stage 2 to 3
breast cancer: clinical and biomarker outcomes and predictive
value of the baseline PAM50-based intrinsic subtype–ACOSOG
Z1031. J Clin Oncol 2011;29(17):2342–2349
21 Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of
fulvestrant 500 mg versus anastrozole 1 mg as first-line
Rev Bras Ginecol Obstet Vol. 38 No. 12/2016
Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer Reinert et al. 621
treatment for advanced breast cancer: results from the FIRST
study. J Clin Oncol 2009;27(27):4530–4535
22 Robertson JF, Llombart-Cussac A, Felti D, et al. Fulvestrant 500 mg
versus anastrozole as first-line treatment for advanced breast
cancer: overall survival from the phase II ‘first’ study (Abstract).
In: Proceedings of the San Antonio Breast Cancer Symposium;
2014 Dec 9–13; San Antonio, USA. p. S6–04.
23 Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM
phase III trial comparing fulvestrant 250 mg with fulvestrant
500 mg in postmenopausal women with estrogen receptor-posi-
tive advanced breast cancer. J Clin Oncol 2010;28(30):4594–4600
24 Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival:
fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
J Natl Cancer Inst 2014;106(1):djt337
25 Lerebours F, Bourgier C, Alran S, Mouret-Fourme E. Abstract
PD07–04: A randomized phase II neoadjuvant trial evaluating
anastrozole and fulvestrant efficiency for post-menopausal ER-
positive, HER2-negative Breast Cancer patients:first results of the
UNICANCER CARMINA 02 French trial. Cancer Res 2012;72(24,
Suppl)PD07–PD04
26 Smith IE, Dowsett M, Ebbs SR, et al; IMPACT Trialists Group.
Neoadjuvant treatment of postmenopausal breast cancer with
anastrozole, tamoxifen, or both in combination: the Immediate
Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxi-
fen (IMPACT) multicenter double-blind randomized trial. J Clin
Oncol 2005;23(22):5108–5116
27 Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastro-
zole versus tamoxifen as preoperative therapy in postmenopausal
women with hormone receptor-positive breast cancer: the Pre-
Operative “Arimidex” Compared to Tamoxifen (PROACT) trial.
Cancer 2006;106(10):2095–2103
28 Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen
receptor-positive breast cancer based on postneoadjuvant endo-
crine therapy tumor characteristics. J Natl Cancer Inst 2008;
100(19):1380–1388
29 Dixon JM, Renshaw L, Macaskill EJ, et al. Increase in response rate
by prolonged treatment with neoadjuvant letrozole. Breast Can-
cer Res Treat 2009;113(1):145–151
30 Llombart-Cussac A, Guerrero Á, Galán A, et al. Phase II trial with
letrozole to maximum response as primary systemic therapy in
postmenopausal patients with ER/PgR[þ] operable breast cancer.
Clin Transl Oncol 2012;14(2):125–131
31 Fontein DB, Charehbili A, Nortier JW, et al. Efficacy of six month
neoadjuvant endocrine therapy in postmenopausal, hormone
receptor-positive breast cancer patients–a phase II trial. Eur J
Cancer 2014;50(13):2190–2200
32 Krainick-Strobel UE, Lichtenegger W, Wallwiener D, et al. Neo-
adjuvant letrozole in postmenopausal estrogen and/or progester-
one receptor positive breast cancer: a phase IIb/III trial to
investigate optimal duration of preoperative endocrine therapy.
BMC Cancer 2008;8:62
33 Carpenter R, Doughty JC, Cordiner C, et al. Optimum duration of
neoadjuvant letrozole to permit breast conserving surgery. Breast
Cancer Res Treat 2014;144(3):569–576
34 Barroso-Sousa R, Silva DD, Alessi JV, Mano MS. Neoadjuvant
endocrine therapy in breast cancer: current role and future
perspectives. Ecancermedicalscience 2016;10:609
35 Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2
randomized trial of primary endocrine therapy versus chemo-
therapy in postmenopausal patients with estrogen receptor-
positive breast cancer. Cancer 2007;110(2):244–254
36 Alba E, Calvo L, Albanell J, et al; GEICAM. Chemotherapy (CT) and
hormonotherapy (HT) as neoadjuvant treatment in luminal
breast cancer patients: results from the GEICAM/2006-03, a
multicenter, randomized, phase-II study. Ann Oncol 2012;23-
(12):3069–3074
37 Palmieri C, Cleator S, Kilburn LS, et al. NEOCENT: a randomised
feasibility and translational study comparing neoadjuvant endocrine
therapy with chemotherapy in ER-rich postmenopausal primary
breast cancer. Breast Cancer Res Treat 2014;148(3):581–590
38 Francis PA, Regan MM, Fleming GF, et al; SOFT Investigators;
International Breast Cancer Study Group. Adjuvant ovarian sup-
pression in premenopausal breast cancer. N Engl J Med 2015;
372(5):436–446
39 Pagani O, Regan MM, Walley BA, et al; TEXT and SOFT Investi-
gators; International Breast Cancer Study Group. Adjuvant
exemestane with ovarian suppression in premenopausal breast
cancer. N Engl J Med 2014;371(2):107–118
40 Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of
neoadjuvant pertuzumab and trastuzumab inwomenwith locally
advanced, inflammatory, or early HER2-positive breast cancer
(NeoSphere): a randomisedmulticentre, open-label, phase 2 trial.
Lancet Oncol 2012;13(1):25–32
41 Cortazar P, Zhang L, Untch M, et al. Pathological complete re-
sponse and long-term clinical benefit in breast cancer: the
CTNeoBC pooled analysis. Lancet 2014;384(9938):164–172
42 Symmans WF, Peintinger F, Hatzis C, et al. Measurement of
residual breast cancer burden to predict survival after neoadju-
vant chemotherapy. J Clin Oncol 2007;25(28):4414–4422
43 Thomas JS, Julian HS, Green RV, Cameron DA, Dixon MJ. Histopa-
thology of breast carcinoma following neoadjuvant systemic
therapy: a common association between letrozole therapy and
central scarring. Histopathology 2007;51(2):219–226
44 Dowsett M, Smith IE, Ebbs SR, et al; IMPACT Trialists Group.
Prognostic value of Ki67 expression after short-term presurgical
endocrine therapy for primary breast cancer. J Natl Cancer Inst
2007;99(2):167–170
45 Dowsett M, Smith IE, Ebbs SR, et al; IMPACT Trialists. Short-term
changes in Ki-67 during neoadjuvant treatment of primary breast
cancer with anastrozole or tamoxifen alone or combined correlate
with recurrence-free survival. Clin Cancer Res 2005;11(2 Pt 2):
951s–958s
46 Sanati S, Suman VJ, Goncalves R, DeSchryver K, Ma CX, Hoog J,
et al. Validation of the preoperative endocrine prognostic index in
the ACOSOG (Alliance) Z1031 neoadjuvant aromatase inhibitor
trial [abstract P4]. Cancer Res 2015;75(9, Suppl):11–13
47 Ellis MJ, Suman V, McCall L, et al. Z1031B: neoadjuvant aromatase
inhibitor trial: aphase2studyof triage tochemotherapybasedon2 to
4 week Ki67 level> 10%. Cancer Res 2012;72(24, Suppl):PD07–PD01
48 Goncalves R, Ma C, Luo J, Suman V, Ellis MJ. Use of neoadjuvant
data to design adjuvant endocrine therapy trials for breast cancer.
Nat Rev Clin Oncol 2012;9(4):223–229
49 López-Knowles E, Gao Q, Cheang MC, et al; POETIC trialists.
Heterogeneity in global gene expression profiles between biopsy
specimens taken peri-surgically from primary ER-positive breast
carcinomas. Breast Cancer Res 2016;18(1):39
50 Dowsett M, Smith I, Robertson J, et al. Endocrine therapy, new
biologicals, and new study designs for presurgical studies in
breast cancer. J Natl Cancer Inst Monogr 2011;2011(43):120–123
51 Semiglazov V, Kletsel V, Semiglazov V, et al. Exemestane (E) vs
tamoxifen (T) as neoadjuvant endocrine therapy for postmeno-
pausal women with ERþ breast cancer (T2N1–2, T3N0–1,
T4N0M0). J Clin Oncol 2005;23(16, Suppl):530
52 Chiba A. Neoadjuvant endocrine use in the U.S. for hormone
receptor positive breast cancer: results from the National Cancer
Data Base. Abstract of the Society of Surgical Oncology Annual
Cancer Symposium; 2016. Abst. 19.
53 Eiermann W, Paepke S, Appfelstaedt J, et al; Letrozole Neo-
Adjuvant Breast Cancer Study Group. Preoperative treatment of
postmenopausal breast cancer patients with letrozole: A ran-
domized double-blind multicenter study. Ann Oncol 2001;12-
(11):1527–1532
54 Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole
versus tamoxifen in patients receiving goserelin for premeno-
pausal breast cancer (STAGE): a double-blind, randomised phase
3 trial. Lancet Oncol 2012;13(4):345–352
Rev Bras Ginecol Obstet Vol. 38 No. 12/2016
Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer Reinert et al.622
